Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorWang, Kang
dc.contributor.authorZerdes, Ioannis
dc.contributor.authorJohansson, Henrik
dc.contributor.authorSarhan, Dhifaf
dc.contributor.authorSun, Yizhe
dc.contributor.authorKanellis, Dimitrios
dc.contributor.authorMezheyeuski, Artur
dc.date.accessioned2024-05-15T07:09:54Z
dc.date.available2024-05-15T07:09:54Z
dc.date.issued2024-05-07
dc.identifier.citationWang K, Zerdes I, Johansson HJ, Sarhan D, Sun Y, Kanellis DC, et al. Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer. Nat Commun. 2024 May 7;15:3837.
dc.identifier.issn2041-1723
dc.identifier.urihttps://hdl.handle.net/11351/11459
dc.descriptionImmunometabolism; Breast cancer
dc.description.abstractAlthough metabolic reprogramming within tumor cells and tumor microenvironment (TME) is well described in breast cancer, little is known about how the interplay of immune state and cancer metabolism evolves during treatment. Here, we characterize the immunometabolic profiles of tumor tissue samples longitudinally collected from individuals with breast cancer before, during and after neoadjuvant chemotherapy (NAC) using proteomics, genomics and histopathology. We show that the pre-, on-treatment and dynamic changes of the immune state, tumor metabolic proteins and tumor cell gene expression profiling-based metabolic phenotype are associated with treatment response. Single-cell/nucleus RNA sequencing revealed distinct tumor and immune cell states in metabolism between cold and hot tumors. Potential drivers of NAC based on above analyses were validated in vitro. In summary, the study shows that the interaction of tumor-intrinsic metabolic states and TME is associated with treatment outcome, supporting the concept of targeting tumor metabolism for immunoregulation.
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofseriesNature communications;15(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Aspectes genètics
dc.subjectRegulació genètica
dc.subjectMetabolisme
dc.subject.meshBreast Neoplasms
dc.subject.mesh/metabolism
dc.subject.meshTumor Microenvironment
dc.subject.meshCell Line, Tumor
dc.subject.meshChemotherapy, Adjuvant
dc.titleLongitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41467-024-47932-y
dc.subject.decsneoplasias de la mama
dc.subject.decs/metabolismo
dc.subject.decsmicroambiente tumoral
dc.subject.decslínea celular tumoral
dc.subject.decsquimioterapia adyuvante
dc.relation.publishversionhttps://doi.org/10.1038/s41467-024-47932-y
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Wang k] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. [Zerdes I] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Theme Cancer, Karolinska University Hospital and Karolinska Comprehensive Cancer Center, Stockholm, Sweden. [Johansson HJ] Department of Oncology-Pathology, Karolinska Institutet, and Science for Life Laboratory, Stockholm, Sweden. [Sarhan D, Sun Y] Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden. [Kanellis DC] Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. [Mezheyeuski A] Department of Immunology, Genetics and Pathology, Uppsala University, Rudbeck Laboratory, Uppsala, Sweden. Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid38714665
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record